FDA panel considers first pill for ragweed allergy

January 28, 2014 by Steven Reinberg, Healthday Reporter
FDA panel considers first pill for ragweed allergy
Placed under the tongue, it helps the body immunize itself against the offending plant.

(HealthDay)—There may be good news coming in the form of a pill for the millions of Americans who suffer from ragweed allergy.

On Tuesday, the U.S. Food and Drug Administration's Allergenic Products Advisory Committee will consider whether to recommend approval of the first to prevent this annual scourge.

Ragwitek, the brainchild of Merck & Co., is made of ragweed pollen and helps the body become immune to it. Patients begin taking the pill, which is placed under the tongue, 12 weeks before the ragweed pollen season begins and continue through the season's end. In the United States, the ragweed season usually starts in September and runs through the fall.

People suffering from ragweed suffer stuffy noses with sneezing, itching and congestion, as well as itchy and watery eyes. These annoying symptoms can affect quality of sleep and hamper daily activities. Plus, these problems often precede the development of asthma.

Current treatments include a variety of nasal sprays, as well as shots specifically tailored to tame all of a patient's allergies.

Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, has his doubts about the power of this new pill. He said people who are allergic to ragweed often are allergic to other plants as well.

"I am skeptical that the pill will work on these other plant allergies," he said.

Another expert, however, said he sees this as a first step in making this kind of allergy treatment a real possibility.

"The whole idea of [under-the-tongue] immunotherapy has been in the background for some time," said William Blouin, an allergy and immunology nurse practitioner at Miami Children's Hospital. "Until this point, immunotherapy has to be done as a series of injections."

A pill would make life simpler, he said, because it wouldn't require the inconvenience of weekly doctor visits or the pain of injections. Blouin said the new pill is intended only for ragweed, so if a person was allergic to other plants it would mean taking a separate pill for each one.

"I understand that there are one or two similar pills in the pipeline," he said.

Last December, the same FDA advisory committee voted unanimously to recommend approval of a similar kind of pill for grass pollen allergies, known as Grastek. Merck is developing that pill in partnership with a European company.

"Conceptually, it's very desirable, especially for children," Blouin said. Although the pill has been tested only on adults, he said he expects it will be tested on teens and young children at some point.

During Tuesday's committee meeting, the panel will be asked whether the data supports the safety and effectiveness of Ragwitek for people aged 18 and older, and whether more studies are needed before making a recommendation to approve the product.

Merck's five trials showed both improvement in symptoms and in quality of life among those who were taking Ragwitek, the company said.

According to FDA documents, some patients experienced lip swelling, abdominal pain and diarrhea while taking the pill. Other side effects included swollen tongue, difficulty breathing and hives.

Explore further: Merck says FDA reviewing its ragweed allergy therapy

More information: Visit the American College of Allergy, Asthma and Immunology for more on ragweed allergy.

Related Stories

Merck says FDA reviewing its ragweed allergy therapy

May 8, 2013
Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Study demonstrates that once-a-day pill offers relief from ragweed allergy symptoms

May 7, 2013
An international team of researchers, led by physician-scientists at Johns Hopkins, reports that a once-daily tablet containing a high dose of a key ragweed pollen protein effectively blocks the runny noses, sneezes, nasal ...

Merck: FDA reviewing tablet to eliminate allergy

March 27, 2013
Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

Holiday health: Asthma with a side of allergies

November 8, 2013
People with asthma traveling to pet friendly homes for the holidays may want to pack allergy medication along with their inhaler. A study being presented this week at the American College of Allergy, Asthma and Immunology's ...

FDA panel again rejects wider use of J&J's Xarelto

January 16, 2014
A panel of Food and Drug Administration experts again opposed expanding use of Johnson & Johnson's blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

That may not be a cold, could be fall allergies

September 25, 2012
(HealthDay)—Many parents complain that as soon as school starts, their child inevitably catches a cold. But, while kids do swap their fair share of germs during the school day, not every runny nose stems from a cold—often, ...

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.